Bernstein analyst Justin Smith maintained a Buy rating on Roche Holding AG (RHHVF – Research Report) today and set a price target of CHF340.00.

Roche said on Thursday it is targeting a continued increase in adjusted earnings per share (EPS) at a high single-digit percentage this year, helped by lower costs and growth from drugs such as eye ...

Roche has a big problem. With competition threatening some of its older and most lucrative biologic drugs, the Swiss pharmaceutical giant expects that, between 2023 and 2028, sales from these assets ...

In a report released today, James Quigley from Goldman Sachs maintained a Sell rating on Roche Holding AG (RHHVF – Research Report), with a price target of CHF269.00. The company’s shares ...

Thomas Roche, 27, was last seen at 12:30 BST on 6 October when he left the flat he shared with his girlfriend in Chester Close, Bletchley, Buckinghamshire, for a cigarette. His sister Carly Roche ...

Roche share price performance has been flattish of late, but that's good for some relative outperformance as the pharmaceutical sector has underperformed. Roche has seen further clinical setbacks ...

Nevertheless, it’s Roche that’s been tipped to stand at the front of the pack when it comes to prescription sales overall in 2025. Evaluate acknowledged that Roche’s projected position as ...

Roche is wasting no time in getting out its checkbook in 2025, signing a new biobucks-heavy pact that aims to add another new antibody-drug conjugate (ADC) to its pipeline. Roche, which put ...